Regen BioPharma Inc
regenbiopharmainc.comWhat Do They Do?
Develops cell and drug candidates for cancer and bone-marrow disorders, and licenses development and commercialization rights to other companies.
10-K for FY2025, filed Dec 30, 2025We were incorporated April 24, 2012 under the laws of the State of Nevada. We intend to engage primarily in the development of regenerative…View ↗
HemaXellarate : HemaXellarate is a cellular composition of autologous stromal vascular fraction derived from adipose tissue. HemaXellarate…View ↗
dCellVax: dCellVax is comprised of autologous dendritic cells which have been treated with an siRNA inhibitor of…View ↗
DiffronC: This drug is intended to use our proprietary siRNA in vivo to inhibit cancer growth and activate T cells. The siRNA targets…View ↗
DuraCar: DuraCar is comprised of CAR-T cells which have been treated with an shRNA targeting the gene NR2F6. By inhibiting NR2F6, we expect…View ↗
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby…View ↗
How Do They Make Money?
Drug companies pay one-time license fees, annual payments under some agreements, and royalties tied to sales of licensed products; the company earns fees when agreed conditions are met and royalties under the sales terms in its license agreements.
10-K for FY2025, filed Dec 30, 2025Pursuant to the Agreement, Zander shall pay to Regen one-time, non-refundable, upfront payment of one hundred thousand US dollars…View ↗
Pursuant to the Agreement, Zander shall pay to Regen royalties equal to four percent (4%) of the Net Sales , as such term is defined in the…View ↗
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021 (b) pay to Regen royalties equal to five percent (5%) of the…View ↗
Revenues from continuing operations were $236,561 for the fiscal year ended September 30, 2025 and $236,560 for the same period ended 2024.…View ↗
The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees.…View ↗
$236.6K
-
10-K for FY2025, filed Dec 30, 2025
$236.6K ↗
Who Are Their Customers?
Other drug developers license intellectual property directly, including Zander Therapeutics and Oncology Pharma. The company also expects to work with outside entities through licensing or sublicensing agreements.
10-K for FY2025, filed Dec 30, 2025On June 23, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. (“Zander”) whereby…View ↗
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby…View ↗
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL…View ↗
It is anticipated that Regen and /or KCL will enter into licensing and/or sublicensing agreements with outside entities in order that Regen…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Aug 17, 2026
−$637.8KView ↗
- ▲ +281% (Loss)
- vs −$167.3K in Q3 FY2025
-
Jul 15, 2026
Company replaces its independent accounting firm
Simon & Edward LLP replaced BCRG as the company's independent registered public accounting firm.
Sources
8-K, filed Jul 15, 2026
Regen Biopharma Inc. (the “Company”), was notified that Simon & Edward LLP (“S&E”) acquired, effective as of June 15, 2026, the attest…View ↗
Growing. Revenue grew 3.9x in 4 years, from $61.2K in FY2021 to $236.6K in FY2025, about 40% a year.
Loading...
